Parkinson's disease (PD) is a multisystem disorder considered the second most common neurodegenerative disease worldwide of which neuroprotective therapies are not yet available. PD is known mainly by its cardinal motor symptoms which are believed to be associated with dopamine deficiency in the nigrostriatal pathway as a result of DAergic neurons degeneration in the substantia nigra pars compacta of the midbrain. However, other brain structures degenerate (non-dopaminergic abnormalities) in PD resulting in other symptoms known as non-motor symptoms (NMS). NMS and non-DAergic abnormalities are sometimes present before diagnosis and almost inevitably emerge with the disease progression. Hence, they might play a tremendously important role in the management and sometimes even the diagnosis of PD. This chapter will provide an overview on the neuropathobiology of NMS in PD.
Although Parkinson's disease (PD) is the second most common neurological disorder, it faces a lack of credible medications, treatments, and diagnostics. Many current conventional substances are designed as anti-Parkinson's drugs, but their poor brain transfer across the blood-brain barrier (BBB) and bioavailability are a problem. Recently, chitosan (CTS) and its derivatives from arthropod exoskeletons have attracted much attention because of their neuroprotective effects and their ability to transport therapeutic substances across the BBB. CTS and its derivatives have the ability to inhibit apoptosis, oxidative stress, and neuroinflammation. In addition to these properties, CTS nanoparticles constitute a system for the controlled delivery of therapeutic molecules across the BBB. This chapter will focus on the neuroprotective effects of CTS and its derivatives and their applications in the delivery of certain therapeutic substances.
Environmental pollutants (EPs) have become an increasingly common health hazard. Several studies have sustained the impact of these EPs on human gut microbiota (GM). The human GM is made up of thousands of microbes that play a paramount role to maintain hosts' health by providing many physiological functions, as well as protecting the host from pathogens and aggressions. Considering the crucial role that the host's GM plays in maintaining health, its disruption (gut dysbiosis) by the EPs can increase extraordinary the risk of infections and lead to the development of several conditions. Therefore, interventions aimed to restore the gut microbial population are of great interest. This chapter examines the intricate relationship between EPs and GM, highlighting the profound impact of EPs on human health including the development of infections. Additionally, this chapter discusses the potential role of probiotics, prebiotics, and FMT in mitigating the detrimental effects of EPs on GM.
Parkinson's disease (PD) is a progressive neurodegenerative disease representing the most common movement disorder worldwide. It is characterized clinically by its cardinal motor features: bradykinesia, rigidity, postural instability, and resting tremor. The clinical diagnosis of PD is mainly based on the presence of these motor symptoms which differentiate it from the other forms of parkinsonism. However, recently other symptoms known as non-motor symptoms (NMS) are ginning attention because of their negative outcome on PD patients, and they are now included in the clinical diagnosis of the disease. Current lines treatments are generally based on DA replacement and are associated with significant alleviation of motor symptoms and some NMS. However, such treatments have not been shown to decrease or halt the disease progression. Moreover, as the disease progresses, these symptomatic treatments can worsen the disease diagnosis and management. Request access from your librarian to read this chapter's full text.
Glial cells, although often overlooked in comparison with neurons, play a crucial role in the structure and function of the nervous system. Their loss can lead to impairment of functions such as learning and memory, contributing to neurodegenerative diseases. To combat these diseases effectively, therapeutic strategies must restore the function of neuronal and glial cells. Natural resources offer promising therapeutic molecules for the treatment of neurodegenerative diseases. Chitosan (CTS), chitooligosaccharide (COS) and their derivatives from arthropod exoskeletons have attracted the attention of neuroscientists because of their neuroprotective effects and their ability to transport therapeutic substances across the blood-brain barrier (BBB). This chapter explores the role of natural resources in the fight against neuronal diseases. Request access from your librarian to read this chapter's full text.
Microglia are the resident macrophages of the central nervous system (CNS). These cells of mesodermal/mesenchymal origin migrate into all regions of the CNS. Recent studies indicate that even in the normal brain, microglia have highly motile processes by which they scan their territorial domains. By a large number of signaling pathways, they can communicate with macroglial cells (e.g. astrocytes) and neurons and with cells of the immune system. Under normal physiological conditions, microglia constantly monitor their microenvironment and survey neurons. Microglia have other functions including the participation in the formation of new blood vessels or angiogenesis, cognitive function, the regulation of synaptic plasticity, and neurogenesis and they play a crucial role in the CNS through communication with other brain cells. This chapter will provide an overview of the functions of microglial cells within the CNS. Request access from your librarian to read this chapter's full text.